Drug · FAERS side-effect profile with label screen

Ocrelizumab and Hyaluronidase side effects: what 7,314 FDA adverse event reports show

Ocrelizumab And Hyaluronidase · 10 reaction terms · 182 drug–reaction co-reports · data 2026-09-14

Drug class

CD20-directed Cytolytic Antibody

FDA label (Established Pharmacologic Class) of the closest related product

Label matched

Ocrelizumab (Ocrevus)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

7,314 reports · 64% serious · 237 with death outcome · 70% female

openFDA FAERS counts, all years, deduplication not applied

Used for

OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more.

FDA label, Indications and Usage

What it is

Ocrelizumab is a recombinant humanized monoclonal antibody directed against CD20-expressing B-cells. Ocrelizumab is a glycosylated immunoglobulin G1 (IgG1) with a molecular mass of approximately 145 kDa.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 8 strongest signals

Labeled (related wording) 5Likely indication confounding 1Not in label — unassessed 2

What the badges mean

Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 2 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Injection site erythema (redness where injected)	45	19.0 14.4–25.0ROR 21.2 · χ² 753 / p 6e-166	18.8 EB05 14.6 · IC025 +3.5 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Multiple sclerosis relapse	21	15.8 10.4–24.0ROR 16.6 · χ² 278 / p 1e-62	15.3 EB05 10.2 · IC025 +2.8 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Injection site reaction	18	13.7 8.7–21.4ROR 14.2 · χ² 199 / p 2e-45	12.8 EB05 8.0 · IC025 +2.6 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Injection site pain (pain where injected)	59	10.1 8.0–12.8ROR 11.7 · χ² 482 / p 3e-107	9.8 EB05 7.8 · IC025 +2.8 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Injection site swelling	13	8.9 5.2–15.2ROR 9.2 · χ² 84 / p 2e-20	7.4 EB05 4.4 · IC025 +1.8 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Injection site rash	5	8.6 3.6–20.5ROR 8.7 · χ² 26 / p 1e-7	5.5 EB05 2.4 · IC025 +0.8 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Multiple sclerosis	7	7.6 3.6–15.8ROR 7.7 · χ² 34 / p 3e-9	5.4 EB05 2.8 · IC025 +1.1 3/3 methods agree	Likely indication confounding term in indications; also in warnings	–	no trial data cached
Injection site pruritus	8	6.3 3.1–12.4ROR 6.4 · χ² 30 / p 2e-8	4.8 EB05 2.6 · IC025 +1.0 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Injection site pain (pain where injected)	59	10.1 8.0–12.8ROR 11.7 · χ² 482 / p 3e-107	9.8 EB05 7.8 · IC025 +2.8 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Injection site erythema (redness where injected)	45	19.0 14.4–25.0ROR 21.2 · χ² 753 / p 6e-166	18.8 EB05 14.6 · IC025 +3.5 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Multiple sclerosis relapse	21	15.8 10.4–24.0ROR 16.6 · χ² 278 / p 1e-62	15.3 EB05 10.2 · IC025 +2.8 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Injection site reaction	18	13.7 8.7–21.4ROR 14.2 · χ² 199 / p 2e-45	12.8 EB05 8.0 · IC025 +2.6 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Injection site swelling	13	8.9 5.2–15.2ROR 9.2 · χ² 84 / p 2e-20	7.4 EB05 4.4 · IC025 +1.8 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Injection site pruritus	8	6.3 3.1–12.4ROR 6.4 · χ² 30 / p 2e-8	4.8 EB05 2.6 · IC025 +1.0 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Multiple sclerosis	7	7.6 3.6–15.8ROR 7.7 · χ² 34 / p 3e-9	5.4 EB05 2.8 · IC025 +1.1 3/3 methods agree	Likely indication confounding term in indications; also in warnings	–	no trial data cached
Injection site rash	5	8.6 3.6–20.5ROR 8.7 · χ² 26 / p 1e-7	5.5 EB05 2.4 · IC025 +0.8 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Injection site discolouration	3	12.6 4.1–38.9ROR 12.7 · χ² 21 / p 2e-6	6.4 EB05 2.0 · IC025 +0.2 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Injection site discomfort	3	15.1 4.9–46.7ROR 15.2 · χ² 27 / p 1e-7	7.9 EB05 2.2 · IC025 +0.3 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Ocrelizumab and Hyaluronidase?

In FDA FAERS, the most frequently co-reported reaction terms for Ocrelizumab and Hyaluronidase are injection site pain, injection site erythema, multiple sclerosis relapse, injection site reaction, injection site swelling, injection site pruritus. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Ocrelizumab and Hyaluronidase have an FDA boxed warning?

No. The FDA label retrieved for Ocrelizumab and Hyaluronidase has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Ocrelizumab and Hyaluronidase causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 9da42362-3bb5-4b83-b4bb-b59fd4e55f0d, effective 20260514; matched on openfda.generic_name.exact:"OCRELIZUMAB")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 10 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.